Notícias

European equities traded in the US as American depositary receipts were tracking slightly lower Thur

Novo Nordisk (NVO) closed the most recent trading day at $38.17, moving 3.12% from the previous trading session.

The U.S. now accounts for more than half of Novo Nordisk’s revenue.

NVO stock is down 11% this week, on track for its worst week since late February if losses hold.

Recent weight gain was associated with a higher likelihood of losing at least 10% of body weight.

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Novo Nordisk (NYSE:NVO) (NYSE:NVO), the Danish drugmaker, would be open to considering a direct listing of its shares on the New York Stock Exchange, according to chief executive Mike Doustdar. Doustdar told the Financial Times that he could see advantages to such a move, although he...

Ozempic Maker Novo Nordisk Eyes Major New Hair-Loss Opportunity

All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.

NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.

Viking Therapeutics' shares jump 36% as VK2735 maintenance data show most weight loss is preserved with less-frequent dosing.

Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.

Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO) stock dropped sharply on Monday after the company laid out new long-term goals that failed to convince investors it can hold its ground against fast-growing rivals in the weight loss drug market.

Meta’s annual conference kicks off today, and the latest on Anthropic's IPO, but this is the next big AI catalyst.

"The growth is mainly due to Novo’s sales and production in the U.S. market at the beginning of this year."

Novo Nordisk (NYSE:NVO) would be open to considering a direct listing of its shares on the New York Stock Exchange, Chief Executive Mike Doustdar told the Financial Times in an interview published Wednesday. Doustdar said he could see advantages to such a move when asked about the possibility, although he clarified that the Danish pharmaceutical company is not currently exploring a change to its U.

Novo Nordisk (NVO) has won approval from Singapore authorities for the use of its weight-loss drug,

Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.

The company aims to launch more than five potential blockbuster drugs by 2030.

Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?

The San Diego company is trying to carve out a place beside Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy with a dual GLP-1/GIP drug that can be given as a shot or, later, a pill.

Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.

RHHBY's enicepatide cut HbA1c and body weight in a phase II study, strengthening its obesity ambitions as it advances the drug into phase III.

Britain’s biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research.

Britain’s biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research.

Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.

The European stock markets closed mixed in Tuesday trading as investors parsed reports that Saudi Ar

The company sees the latest trial results reinforcing its ambitions to rapidly develop a portfolio of medicines for people with obesity, diabetes and cardiovascular disease.

NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stage pipeline.

Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.